Centre for Probe Development and Commercialization

Full-life Technologies Hk Limited

Alla Darwish

John Fitzmaurice Valliant

Eric Steven Burak

Ryan Wayne Simms

John Richard Forbes

Tao Wu

Karin Ann Stephenson

Meiduo Hu

Neil Grant Cockburn

Joel Adamson Drewry

Matthew David Burr Moran

Fa Liu

Stuart James Mahoney

The present application relates to a compound or a pharmaceutically acceptable salt and/or solvate thereof comprising one or more circulation enhancing groups, one or more target binding groups, one or more chelating groups, at one least cleavable linker and at least one branching group that is at least trivalent. The application further includes a radionuclide complex or a pharmaceutically acceptable salt and/or solvate thereof, comprising a compound of the application or a pharmaceutically acceptable salt and/or solvate thereof, and one or more radionuclides, and to compositions comprising the compound or the complexes. The present application also includes methods of using the compounds, complexes and compositions for targeting and/or killing target cells. For example, the compound includes a compound of Formula I

Cleavable radioligands for targeting cell surface receptors and uses thereof

The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.

Residualizing linkers and uses thereof

The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.

IGF-1R monoclonal antibodies and uses thereof

Pharmacokinetic enhancements of bifunctional chelates and uses thereof

Growing community of inventors

Kitchener, Canada

Alla Darwish